The Cancer Letter

Inside information on cancer research and drug development

Vol.
28
No.
25
June 21, 2002Jun 21, 2002
Free
DOWNLOAD THE PDF

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

SEC Notifies ImClone It May Bring Action Against Company

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study

NCAB Grants Three MERIT Awards; Rimer To Leave NCI For Post At UNC

NRSAs Renamed For Kirschstein.

Login

Looking for IP Login?